

IND SWIFT LABORATORIES INC.

**AUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
December 31, 2020**



Vishaw Sondhi, CPA, P.C.

Tax, Accounting & Wealth Management Services

Main Office: 100 Broad Street
Eatontown, NJ 07724

Iselin Office: 870 Green Street
Iselin, NJ 08830

April 23, 2021

INDEPENDENT AUDITOR'S REPORT

**To the Stockholder's
Ind Swift Laboratories, Inc.**

We have audited the accompanying balance sheet of Ind Swift Laboratories, Inc. as of December 31, 2020 and the related statements of income and retained earnings for the period then ended. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Ind Swift Laboratories, Inc. as of December 31, 2020, and the results of its operations and its cash flows for the year then ended, in conformity with generally accepted accounting principles.

Vishaw Sondhi, CPA
Certified Public Accountant

IND SWIFT LABORATORIES, INC.

**BALANCE SHEET
DECEMBER 31, 2020 AND 2019**

ASSETS

	<u>2020</u>	<u>2019</u>
Current Assets:		
Cash in Bank	\$ 292,700	\$ 295,126
Accounts Receivable- Trade	4,484,687	3,630,181
Overpayment of taxes	1,285	-
Other Receivable	2,472	218,502
Total Current Assets	<u>4,781,144</u>	<u>4,143,809</u>
 Furniture and Equipments	 60,494	 60,494
Accumulated Depreciation	<u>(60,494)</u>	<u>(60,494)</u>
 Other Assets - Security Deposit	 -	 3,815
Total Assets	<u>4,781,144</u>	<u>4,147,624</u>

LIABILITIES & STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts Payable	3,476,134	3,034,489
Taxes Payable	32,802	31,207
Other Payable	56,031	54,654
Total Current Liabilities	<u>3,564,967</u>	<u>3,120,350</u>

Stockholders' Equity

Common Stock, no par value, 1500 Shares authorized, 1204 shares issued and outstanding	1,204,000	1,204,000
Retained Earning/ (Deficit)	(176,726)	(285,190)
Net Income	188,904	108,464
Total Partner's Equity	<u>\$ 1,216,178</u>	<u>\$ 1,027,274</u>

Total Liabilities & Stockholders' Equity	<u>\$ 4,781,144</u>	<u>\$ 4,147,624</u>
-----------------------------------------------------	----------------------------	----------------------------

IND SWIFT LABORATORIES, INC

STATEMENT OF OPERATIONS & RETAINED EARNINGS FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

	Qtr Ended Dec-20	Qtr Ended Dec-19	Year Ended Dec-20	Year Ended Dec-19
Income				
Gross Sales	\$ 2,473,898	\$ 2,976,436	\$ 11,248,248	\$ 8,109,473
Net Sales	<u>2,473,898</u>	<u>2,976,436</u>	<u>11,248,248</u>	<u>8,109,473</u>
Cost of Sales				
Cost of Goods Sold	2,206,453	2,836,726	10,119,276	6,916,742
FDA Fees	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
Gross Profit	<u>267,445</u>	<u>139,710</u>	<u>1,128,972</u>	<u>1,192,731</u>
Expenses:				
Selling, General and Administrative	240,428	204,175	865,746	1,063,268
Profit (Loss) before taxes	<u>27,017</u>	<u>(64,465)</u>	<u>263,226</u>	<u>129,463</u>
Taxes on Income	<u>19,252</u>	<u>-</u>	<u>74,322</u>	<u>20,998</u>
Net Income	<u>7,765</u>	<u>(64,465)</u>	<u>188,904</u>	<u>108,465</u>

IND SWIFT LABORATORIES, INC.

**STATEMENT OF CASH FLOW
FOR THE YEAR ENDED DECEMBER 31, 2020 AND 2019**

	<u>2020</u>	<u>2019</u>
Cash Flows from Operating Activities		
Net Income	\$ 188,904	\$ 108,465
Adjustment to reconcile Net Income to		
Net Cash provided by (used in) Operating Activities		
(Increase) Decrease in Other Assets	218,560	(111,044)
(Increase) Decrease in Due to Credit Cards	(2,624)	
(Increase) Decrease in Accounts Receivable	(854,506)	(1,070,365)
(Increase) Decrease in Advance from Customers	-	(311,376)
(Increase) Decrease in Accounts Payable	441,645	1,529,933
(Increase) Decrease in other payable	4,000	10,727
(Increase) Decrease in Taxes Payable	1,595	(3,921)
Net Cash Provided by (Used in) Operating Activities	<u>(2,426)</u>	<u>152,419</u>
Cash Flows from Investing Activities:		-
Purchase of Furniture and Equipments	<u>-</u>	<u>-</u>
Less : Accumulated Depreciation	<u>-</u>	<u>-</u>
Net Cash Provided by (Used in) Investing Activities		
Net Increase (Decrease) in Cash	(2,426)	152,419
Cash Flows from Financing Activities:		-
Return of Equity	-	-
Dividend declared	<u>-</u>	<u>-</u>
Net Cash Provided by (Used in) Financing Activities	-	
Cash- Beginning of Year	<u>295,126</u>	<u>125,282</u>
Cash- End of Year	<u><u>292,700</u></u>	<u><u>277,701</u></u>

IND SWIFT LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2020

This year company has demonstrated successful operations and was instrumental in getting its parent company's manufacturing facility successfully audited by USFDA. This was a CDER initiated CGMP inspection for multiple APIs including high potency products.

During the current year, company commercialized new API in addition to sales of existing API's, for North America. This year company also executed an exclusive supply agreement for one of its products with a North American company.

The company continues to strengthen its CRAMS portfolio with commercial supplies of multiple new and existing products to a reputed US organization from the CRAMS SBU of the parent company.

The company continued commercial quantities of a finished dosage product recently launched in Canadian market. The company is progressing well with its plans with execution of manufacturing and supply agreements with North American generic pharmaceutical companies.